Cancer diagnostics firm Precipio's Q2 revenue rises, adjusted EBITDA turns positive

Precipio

14/08/2026 21:10

Overview
US specialty cancer diagnostics firm's Q2 revenue rose 22% yr/yr to $7.0 mln
Adjusted EBITDA improved to $0.4 mln, driven by higher revenue and lower stock-based compensation
Company ended Q2 with cash exceeding $3 mln, up from $1.1 mln a year earlier

Outlook
Company says it is well positioned to continue building on recent momentum

Result Drivers
CUSTOMER GROWTH - Co said customer growth contributed to quarterly revenue surpassing $7 mln for the first time
PRODUCT REVENUE INCREASE - Product revenues increased 21% from previous high of $750K in Q4-2025
LOWER STOCK-BASED COMPENSATION - Adjusted EBITDA improvement driven in part by decrease in stock-based compensation expense

Company press release: ID:nGNXc1kYVw

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
$7 mln
 

Reuters Recommended Reads
Aug 13 - Co-Diagnostics Q2 revenue rises slightly amid international expansion
Aug 13 - Aktis Oncology Q2 net loss widens on higher R&D, administrative costs
Aug 12 - Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)